A recent study has analyzed data from over 246,822 adults in the United States diagnosed with atherosclerotic heart disease, revealing that the shingles vaccine may extend its benefits beyond just preventing shingles. This research supports the notion that the vaccine could significantly lower the risk of heart disease and even dementia.
Dr. Robert Nguyen, a resident physician at the University of California, Riverside and the study's lead author, stated, "This vaccine has consistently demonstrated cardioprotective effects, reducing the likelihood of heart attacks, strokes, and mortality." He emphasized that these protective benefits may be even more pronounced in high-risk individuals with pre-existing cardiovascular conditions.
Understanding the Heart-Protection Mechanism
The Centers for Disease Control and Prevention (CDC) advises adults aged 50 and older, as well as younger individuals with compromised immune systems, to receive the shingles vaccine. This vaccine combats herpes zoster, which can cause painful rashes and prolonged nerve pain by reactivating the chickenpox virus.
Previous studies indicated that shingles infections could lead to blood clots forming near the heart and brain, thereby elevating the risk of heart attacks, strokes, and venous thromboembolism. By preventing shingles, the vaccine may also mitigate these dangerous clotting risks.
Comprehensive Study Findings
Researchers utilized the TriNetX database, which houses medical records from millions of Americans, to carry out this study. They focused on adults aged 50 and above diagnosed with atherosclerotic disease between 2018 and 2025. The analysis included 123,411 vaccinated individuals who received either the Shingrix or Zostavax vaccine, compared to an equal number of unvaccinated individuals, ensuring demographic and health condition similarities.
The study revealed that vaccinated participants experienced a 46% lower risk of major adverse cardiac events and a 66% reduction in mortality from any cause within one year post-vaccination. Additionally, their chances of having a heart attack decreased by 32%, while the risks of stroke and heart failure dropped by 25% each.
Nguyen highlighted that these reductions are significant, comparable to the advantages of quitting smoking, reinforcing the recommendation for adults over 50 to receive the vaccine. "Vaccines are crucial for disease prevention," he remarked. "In today's climate of misinformation, these findings provide compelling reasons for individuals to get vaccinated."
Future Implications and Considerations
While this analysis primarily tracked outcomes within the first year following vaccination, previous research suggests that shingles vaccination may lead to a 23% decrease in cardiovascular events over a longer duration, potentially lasting up to eight years. However, it is essential to consider that individuals opting for vaccination might also engage in healthier lifestyle choices. Despite adjustments for various health and socioeconomic factors, some benefits observed may still be influenced by these differences. Nevertheless, the study's extensive sample size and rigorous statistical methods lend strong credibility to the association between shingles vaccination and reduced heart risk.
Dr. Nguyen is set to present the findings of this study, "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease," on Monday, March 30, at 12:30 p.m. CT / 17:30 UTC in Posters, Hall E.